Aspreva plans to expand use of CellCept into cardiovascular care, MS

By Elaine Rigoli

Tampa, Fla., Sept. 21 - Aspreva Pharmaceuticals Corp. said it will explore the potential of CellCept for the treatment of cardiovascular disease in autoimmune patients and multiple sclerosis patients.

Aspreva, with a primary focus on autoimmune diseases, has three clinical trial programs underway testing CellCept for lupus nephritis, myasthenia gravis and pemphigus vulgaris, according to president and co-founder Noel Hall, who addressed the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London.

Aspreva, an emerging pharmaceutical company based in Victoria, B.C., said it expects to finish its CellCept trial for lupus nephritis and pemphigus vulgaris in 2007 and finish the treatment of myasthenia gravis in late 2006.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.